ADMA - ADMA Biologics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ADMA is currently covered by 4 analysts with an average price target of $25.62. This is a potential upside of $5.19 (25.4%) from yesterday's end of day stock price of $20.43.

ADMA Biologics's activity chart (see below) currently has 28 price targets and 54 ratings on display. The stock rating distribution of ADMA is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 80.79% with an average time for these price targets to be met of 822.14 days.

Highest price target for ADMA is $26, Lowest price target is $14, average price target is $22.5.

Most recent stock forecast was given by KRISTEN KLUSKA from CANTOR FITZGERALD on 04-Mar-2025. First documented stock forecast 09-Sep-2015.

Currently out of the existing stock ratings of ADMA, 24 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$25

$5.16 (26.01%)

$20

2 months 29 days ago
(04-Mar-2025)

8/9 (88.89%)

$7.99 (46.97%)

138

Buy

$25

$5.16 (26.01%)

$10

6 months 25 days ago
(08-Nov-2024)

5/6 (83.33%)

$2.38 (10.52%)

632

Buy

$26

$6.16 (31.05%)

$18

6 months 25 days ago
(08-Nov-2024)

14/15 (93.33%)

$3.38 (14.94%)

298

$14

$-5.84 (-29.44%)

$12

11 months 13 days ago
(20-Jun-2024)

7/7 (100%)

$3.29 (30.72%)

529

Buy

$4

$-15.84 (-79.84%)

$7

4 years 6 months 27 days ago
(06-Nov-2020)

6/6 (100%)

$2.09 (109.42%)

1736

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ADMA (ADMA Biologics) average time for price targets to be met?

On average it took 822.14 days on average for the stock forecasts to be realized with a an average price target met ratio 80.79

Which analyst has the current highest performing score on ADMA (ADMA Biologics) with a proven track record?

JASON KOLBERT

Which analyst has the current lower performing score on ADMA (ADMA Biologics) with a proven track record?

JASON MCCARTHY

Which analyst has the most public recommendations on ADMA (ADMA Biologics)?

Jason Kolbert has 5 price targets and 6 ratings on ADMA

Which analyst is the currently most bullish on ADMA (ADMA Biologics)?

Raghuram Selvaraju with highest potential upside - $6.16

Which analyst is the currently most reserved on ADMA (ADMA Biologics)?

Leland Gershell with lowest potential downside - -$15.84

ADMA Biologics in the News

ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?

ADMA Biologics ADMA reported lower-than-expected results for the first quarter. Adjusted earnings per share of 14 cents missed the Zacks Consensus Estimate of 16 cents. Revenues of $114.8 million (up 40% year over year) also missed the Zacks Consensus Estimate of $119 million. Consequently, the stock has plunged post the earnings announcement on May 7....

Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits

ADMA stock plummeted Thursday after the biotech company slightly missed the Street’s first-quarter expectations. Continue Reading
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?